期刊文献+

血中维生素D、血钙浓度及组织中钙敏感受体与乳腺癌的相关性研究 被引量:4

Study on serum levels of vitamin D and calcium and expression of tissue calcium-sensing receptor in the breast cancers
原文传递
导出
摘要 目的探讨25-羟基维生素D[25-Hydroxy VitaminD,25(OH)D]、血钙(Serum calcium,Ca2+)以及钙敏感受体(Calcium-sensing receptor,CaSR)与乳腺癌的关系。方法采用酶联免疫法和偶氮胂Ⅲ法检测乳腺癌及乳腺良性肿瘤患者血清25(OH)D和Ca2+水平,采用免疫组织化学S-P法检测乳腺癌、乳腺良性肿瘤和瘤旁正常组织中CaSR的表达情况。结果乳腺癌组血清中25(OH)D水平明显低于乳腺良性病组[(34.13±14.14)nmol/Lvs(50.29±25.65)nmol/L,t=2.870,P=0.001],血清25(OH)D在淋巴结转移阳性乳腺癌患者中的水平明显低于淋巴结转移阴性患者[(30.8±9.71)nmol/LVS(43.7±23.59)nmol/L,t=2.467,P=0.021],乳腺癌组(88.9%)CaSR的阳性表达率明显高于良性乳腺组织(60.0%,χ2=6.717,P〈0.01)和瘤旁正常乳腺组织(60.0%,χ2=5.628,P〈0.05)。结论血清25(OH)D浓度和组织中CaSR的表达可能与乳腺癌的发生、发展及预后有关。 Objective To explore the relationship among 25-hydroxyvitamin D, serum calcium, calcium-sensing receptor, and breast cancer. Methods The expressions of calcium-sensing receptor (CaSR) in primary breast cancer, breast benign tumors, and normal breast tissue beside tumors were determined by immunohistochemistry S-P method as well as the concentration of serum 25 (OH) D and serum calcium in breast cancer and breast benign tumors by Enzyme-linked immunosorbent assay (ELISA), Tribro- moarsenazo Ⅲ method. Results Serum 25 (OH) D level of breast cancer was significantly lower than the breast benign tumors[ (34. 13 ± 14. 14)nmol/L vs (50. 29 ±25.65) nmol/L, t =2. 870, P =0. 001 ]. Serum level of 25 ( OH ) D in lymph node metastasis positive patient was lower than that in negative group [ (30. 8 ± 9.71 ) nmol/L vs (43.7 ± 23.59 ) nmol/L, t = 2. 467, P = 0. 021 ]. The positive expression of CaSR in breast cancer( 88.9% )was higher than breast benign tumors (60%, χ2 = 6. 717, P 〈 0. 01 ) and normal breast tissue beside tumors(60% ,χ2 =5. 628, P 〈0. 05). Conclusions Concentration of serum 25 (OH)D and expression of calcium-sensing receptor in the tissues may be associated with occurrence, development and prognosis of breast cancer.
出处 《中国医师杂志》 CAS 2012年第9期1157-1160,共4页 Journal of Chinese Physician
基金 国家自然基金资助项目(20972046)
关键词 维生素D/血液 钙/血液 受体 钙敏感/分析 乳腺肿瘤 Vitamin D/blood Calcium/blood Receptors, Calcium-sensing/analysis Breast neo- plasms
  • 相关文献

参考文献10

  • 1关爱华,姜伟栋,关文曾.VDR与乳腺癌临床病理因素的关系[J].中国妇幼保健,2006,21(5):692-694. 被引量:5
  • 2Welsh J. Vitamin D and breast cancer: insights from animal mod- els. Am J Clin Nutr,2004,$0(6 Suppl) :1721S-1724S.
  • 3杨春华.维生素D简介[J].中国实用医药,2009,4(3):243-244. 被引量:31
  • 4Colston KW. Vitamin D and breast cancer risk. Best Pract Res Clin Endocrinol Metab,2008,22(4) :587-599.
  • 5Schwartz GG. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann Epidemiol,2009,19(2) :96-102.
  • 6VanHouten JN. Calcium sensing by the mammary gland. J Mam- mary Gland Biol Neoplasia ,2005,10 ( 2 ) : 129-139.
  • 7庄志刚,余剑敏,蒋蓓琦,李正东,庄传经.乳腺癌患者外周血25羟基维生素D测定及临床意义[J].实用医学杂志,2010,26(2):244-246. 被引量:17
  • 8Frazier AL, Li L, Cho E, et al. Adolescent diet and risk of breast cancer. Cancer Causes Control,2004,15 ( 1 ) :73-82.
  • 9Brown EM. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab,2007,3 (2) :122-133.
  • 10Mihai R, Stevens J, McKinney C, et al. Expression of the calci- um receptor in human breast cancer-a potential new marker pre- dicting the risk of bone metastases. Eur J Surg Oncol,2006,32 (5) :511-515.

二级参考文献26

  • 1廖二元.维生素D制剂的药理机制与临床应用[J].中南药学,2003,1(2):98-102. 被引量:12
  • 2刘桂萍.1,25—二羟基维生素D_3的研究进展[J].生物学教学,1994,19(4):4-6. 被引量:3
  • 3张焱,程学新,刘颙颙,王雪松,张宝文.光化学合成维生素D[J].精细与专用化学品,2005,13(5):5-7. 被引量:13
  • 4何彩平.维生素D的生物效应与疾病[J].重庆医学,1995,24(1):56-57. 被引量:1
  • 5Deeb K K, Trump D L, Johnson C S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics [J]. Nature Reviews Cancer, 2007,7 (9) : 684-700.
  • 6Martin L, Harold L, Newmark D. Vitamin D,calcium and prevention of breast cancer : a review [ J ]. Am Colle J Nutr, 1999,5 (18) :392-397.
  • 7VanHouten J N. Calcium sensing by the mammary gland [J]. J Mammary Gland Biol Neoplasia, 2005,10(2) : 129-139.
  • 8Yamaha K, Saito H, Takenouchi K, et al. Vitamin D and cancer [J]. Clin Calcium, 2006, 16(7) : 1147-1153.
  • 9Barbareschi M, Veronese S, Caffo O, et al. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up [J]. HumPathol, 1996,27( 11 ) : 1149 -1155.
  • 10Issa L L, Leong G M, Eisman J A. Molecular mechanism of vitamin D receptor action [J]. Inflamm Res, 1998,47(12) :451-475.

共引文献48

同被引文献82

  • 1王莹,贾海英,司少艳,刘俊丽,孙丽丽,宋淑军.男性维生素D水平与血浆致动脉硬化指数关系的研究[J].中国动脉硬化杂志,2015,23(5):515-518. 被引量:5
  • 2杨光,张祥宏,张静,张志刚,王晓玲,严霞,王俊灵,赵俊京,李智岗.乳腺癌组织中骨桥蛋白和骨连接蛋白的表达及其与微钙化形成的关系[J].中华放射学杂志,2006,40(9):953-956. 被引量:20
  • 3Tuck AB,Chambers AF,Allan AL. Osteopontin overexpression in breast cancer:knowledge gained and possible implications for clinical management[J].{H}Journal of Cellular Biochemistry,2007,(04):859-868.
  • 4Tse GM,Tan PH,Pang AL. Calcification in breast lesions:pathologists' perspective[J].{H}Journal of Clinical Pathology,2008,(02):145-151.
  • 5Baker R,Rogers KD,Shepherd N. New relationships between breast microcalcifications and cancer[J].{H}British Journal of Cancer,2010,(07):1034-1039.
  • 6Alimirah F,Peng X,Murillo G. Functional significance of vitamin D receptor FokI polymorphism in human breast cancer cells[J].PLoS One,2011,(01):e16024.
  • 7Cui Y,Rohan TE. Vitamin D,calcium,and breast cancer risk:a review[J].{H}Cancer Epidemiology Biomarkers & Prevention,2006,(08):1427-1437.
  • 8Rollison DE,Cole AL,Tung KH. Vitamin D intake,vitamin D receptor polymorphisms,and breast cancer risk among women living in the southwestern U.S[J].{H}Breast Cancer Research and Treatment,2012,(02):683-691.
  • 9K(o)stner K,Denzer N,Müller CS. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer:a review of the literature[J].{H}Anticancer Research,2009,(09):3511-3536.
  • 10Li X,Speer MY,Yang H. Vitamin D receptor activators induce an anticalcific paracrine program in macrophages:requirement of osteopontin[J].{H}Arteriosclerosis Thrombosis and Vasoular Biology,2010,(02):321-326.

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部